John F. Robinson

John F. Robinson

Auto-generated profile, based on publicly available information

John F. Robinson

Department of Biochemistry, Schulich School of Medicine and Dentistry, and Robarts Research Institute, Western University, London, Canada

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 2019 in RNA Biology
Verified
Journal Article
Open access
MBMatthew Berg
Matthew Berg
DGDaniel J. Giguere
Daniel J. Giguere
JDJacqueline S. Dron
Jacqueline S. Dron
JLJeremy T. Lant
Jeremy T. Lant
JGJulie Genereaux
Julie Genereaux
CBChristopher J. Brandl
Christopher J. Brandl
Transfer RNAs are required to translate genetic information into proteins as well as regulate other cellular processes. Nucleotide changes in tRNAs can result in loss or gain of function that impact the composition and fidelity of the proteome. Despite links between tRNA variation and disease, the importance of cytoplasmic tRNA variation has been overlooked. Using a custom capture panel, we sequenced 605 human tRNA-encoding genes from 84 individuals. We developed a bioinformatic pipeline that allows more accurate tRNA read mapping and identifies multiple polymorphisms occurring within the same variant. Our analysis identified 522 unique tRNA-encoding sequences that differed from the reference genome from 84 individuals. Each individual had ~66 tRNA variants including nine variants found in less than 5% of our sample group. Variants were identified throughout the tRNA structure with 17% predicted to enhance function. Eighteen anticodon mutants were identified including potentially mistranslating tRNAs; e.g., a tRNASer that decodes Phe codons. Similar engineered tRNA variants were previously shown to inhibit cell growth, increase apoptosis and induce the unfolded protein response in mammalian cell cultures and chick embryos. Our analysis shows that human tRNA variation has been underestimated. We conclude that the large number of tRNA genes provides a buffer enabling the emergence of variants, some of which could contribute to disease.

4 July 2016 in Human Genetics
Verified
Journal Article
Closed access
PDF file
CLCécile Low-Kam
Cécile Low-Kam
DRDavid Rhainds
David Rhainds
KLKen Sin Lo
Ken Sin Lo
SPSylvie Provost
Sylvie Provost
IMIan Mongrain
Ian Mongrain
GLGuillaume Lettre
Guillaume Lettre

1 November 2019 in Journal of Lipid Research
Verified
Journal Article
Open access
PDF file
JDJacqueline S. Dron
Jacqueline S. Dron
JWJian Wang
Jian Wang
AMAdam McIntyre
Adam McIntyre
HCHenian Cao
Henian Cao
JRJohn F. Robinson
John F. Robinson
RHRobert Hegele
Robert Hegele
Jacqueline S. Dron, Jian Wang, Adam D. McIntyre, Henian Cao, John F. Robinson, P. Barton Duell, Priya Manjoo, James Feng, Irina Movsesyan, Mary J. Malloy, Clive R. Pullinger, John P. Kane, Robert A. Hegele

10 January 2013 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
JDJoseph B. Dubé
Joseph B. Dubé
CJChristopher T. Johansen
Christopher T. Johansen
JRJohn F. Robinson
John F. Robinson
JLJoan Lindsay
Joan Lindsay
VHVladimir Hachinski
Vladimir Hachinski
RHRobert Hegele
Robert Hegele
Dementia is a heritable condition with devastating effects on both patients and their caregivers. Studies have identified genetic variants associated with increased susceptibility to late-onset Alzheimer disease (AD)-related dementia; however, no studies have assessed whether genetic variation is associated with the early stages of cognitive decline. Given that cerebrovascular disease is an established mechanism in which chronic ischemia increases susceptibility to dementia, we assessed whether genetic variation associated with either cardio-metabolic or AD-related traits is associated with an early stage of cognitive decline called "cognitive impairment, no dementia" (CIND). We studied 484 CIND patients and 459 cognitively healthy controls selected from the Canadian Study of Health and Aging. We tested for association between ~200,000 genetic variants selected from genes associated with cardio-metabolic traits and CIND status using the Cardio-MetaboChip. We also assessed whether AD-related variants and APOE alleles were associated with CIND status, either individually or as part of a composite genetic risk score. We identified a potential association between the ZNF608/GRAMD3 locus, specifically the rs1439568 polymorphism and CIND status (major allele odds ratio [OR] = 1.51; p = 8.4 × 10(-6)). AD-related variants were not associated with CIND status, however APOE E4 allele frequency was significantly higher in CIND patients versus healthy controls (OR = 1.35; p = 0.044). We identified a potential association between the ZNF608/GRAMD3 locus and CIND status, although AD-related variants were not associated with CIND. Additional replication of this association signal is invited.

2 August 2020 in medRxiv
Verified
Preprint
Open access
PDF file
KSKelly M. Sunderland
Kelly M. Sunderland
DBDerek Beaton
Derek Beaton
SAStephen R. Arnott
Stephen R. Arnott
PKPeter Kleinstiver
Peter Kleinstiver
DKDonna Kwan
Donna Kwan
MBMalcolm A. Binns
Malcolm A. Binns
Objective: In individuals over the age of 65, concomitant neurodegenerative pathologies contribute to cognitive and/or motor decline and can be aggravated by cerebrovascular disease, but our understanding of how these pathologies synergize to produce the decline represents an important knowledge gap. The Ontario Neurodegenerative Disease Research Initiative (ONDRI), a multi-site, longitudinal, observational cohort study, recruited participants across multiple prevalent neurodegenerative diseases and cerebrovascular disease, collecting a wide array of data and thus allowing for deep investigation into common and unique phenotypes. This paper describes baseline features of the ONDRI cohort, understanding of which is essential when conducting analyses or interpreting results. Methods: Five disease cohorts were recruited: Alzheimer’s disease/amnestic mild cognitive impairment (AD/MCI), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Parkinson’s disease (PD), and cerebrovascular disease (CVD). Assessment platforms included clinical, neuropsychology, eye tracking, gait and balance, neuroimaging, retinal imaging, genomics, and pathology. We describe recruitment, data collection, and data curation protocols, and provide a summary of ONDRI baseline characteristics. Results: 520 participants were enrolled. Most participants were in the early stages of disease progression. Participants had a median age of 69 years, a median Montreal Cognitive Assessment score of 25, a median percent of independence of 100 for basic activities of daily living, and a median of 93 for instrumental activities. Variation between disease cohorts existed for age, level of cognition, and geographic location. Conclusion: ONDRI data will enable exploration into unique and shared pathological mechanisms contributing to cognitive and motor decline across the spectrum of neurodegenerative diseases.

1 July 2005 in Clinical Biochemistry
Verified
Journal Article
Closed access
DCDavid E. Carter
David E. Carter
JRJohn F. Robinson
John F. Robinson
EAEmma M. Allister
Emma M. Allister
MHMurray W. Huff
Murray W. Huff
RHRobert Hegele
Robert Hegele